Cencora, Inc. (COR) Return on Invested Capital (ROIC): 13.23%
Is Cencora, Inc.’s return on invested capital (ROIC) high or low?
Cencora, Inc.'s return on invested capital (ROIC) of 13.23% is in line with its 5-year average of 13.58%, around the middle of its 5-year range (11.30%–16.94%).
As of Saturday, June 13, 2026. 12.30% below its 12-month average of 15.09%.
COR Return on Invested Capital (ROIC) Chart
COR Average Return on Invested Capital (ROIC) Chart
COR Current vs Average Return on Invested Capital (ROIC) Chart
COR Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
13.23%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
15.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
14.58%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
13.58%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
11.78%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
12.89%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
12.36%
CURRENT VS TTM AVG
-12.30%
CURRENT VS 3Y AVG
-9.27%
CURRENT VS 5Y AVG
-2.57%
CURRENT VS 10Y AVG
+12.28%
CURRENT VS 15Y AVG
+2.61%
CURRENT VS 20Y AVG
+7.06%
COR Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cencora, Inc. (COR) | $54.80B | 13.23% | 15.09% | 14.58% | 13.58% |
| Becton, Dickinson and Company (BDX) | $52.98B | 4.73% | 4.38% | 4.32% | 3.88% |
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.06B | 8.51% | 9.70% | 12.91% | 18.22% |
| Humana Inc. (HUM) | $45.53B | 3.12% | 3.25% | 5.37% | 7.01% |
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 40.27% | 37.07% | 34.89% | 35.94% |
| Agilent Technologies, Inc. (A) | $36.67B | 12.57% | 12.57% | 13.57% | 12.73% |
| Zoetis Inc. (ZTS) | $33.36B | 21.54% | 21.87% | 20.30% | 19.27% |
| Centene Corporation (CNC) | $32.19B | -13.41% | -4.17% | -0.53% | 0.76% |
| Medline Inc. (MDLN) | $30.96B | 5.69% | 6.03% | 3.95% | 3.95% |
| Cigna Corporation (CI) | $78.83B | 7.35% | 7.02% | 7.07% | 6.50% |
Capital Efficiency
ROIC
13.2%
ROE
75.0%
Cencora, Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Cencora, Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Cencora, Inc. (COR)?
- The return on invested capital (ROIC) for COR stock is 13.23%.
- Is Cencora, Inc.'s return on invested capital (ROIC) high or low?
- Cencora, Inc.'s return on invested capital (ROIC) of 13.23% is in line with its 5-year average of 13.58%, around the middle of its 5-year range (11.30%–16.94%).
- What is the TTM average return on invested capital (ROIC) for Cencora, Inc. (COR)?
- The TTM average return on invested capital (ROIC) for COR stock is 15.09%.
- What is the 3Y average return on invested capital (ROIC) for Cencora, Inc. (COR)?
- The 3Y average return on invested capital (ROIC) for COR stock is 14.58%.
- What is the 5Y average return on invested capital (ROIC) for Cencora, Inc. (COR)?
- The 5Y average return on invested capital (ROIC) for COR stock is 13.58%.
- What is the 10Y average return on invested capital (ROIC) for Cencora, Inc. (COR)?
- The 10Y average return on invested capital (ROIC) for COR stock is 11.78%.
- What is the 15Y average return on invested capital (ROIC) for Cencora, Inc. (COR)?
- The 15Y average return on invested capital (ROIC) for COR stock is 12.89%.
- What is the 20Y average return on invested capital (ROIC) for Cencora, Inc. (COR)?
- The 20Y average return on invested capital (ROIC) for COR stock is 12.36%.
Cencora, Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-09-30 | 13.23% |
| 2024-09-30 | 16.94% |
| 2023-09-30 | 13.48% |
| 2022-09-30 | 14.68% |
| 2021-09-30 | 11.30% |
| 2020-09-30 | 11.84% |
| 2019-09-30 | 16.94% |
| 2018-09-30 | 16.59% |
| 2017-09-30 | 9.36% |
| 2016-09-30 | 18.77% |
| 2015-09-30 | -13.52% |
| 2014-09-30 | 11.68% |
| 2013-09-30 | 14.62% |
| 2012-09-30 | 18.48% |
| 2011-09-30 | 17.02% |
| 2010-09-30 | 14.89% |
| 2009-09-30 | 13.64% |
| 2008-09-30 | 12.52% |
| 2007-09-30 | 11.11% |
| 2006-09-30 | 8.64% |
| 2005-09-30 | 7.30% |
| 2004-09-30 | 9.27% |
| 2003-09-30 | 9.18% |
| 2002-09-30 | 8.37% |
| 2001-09-30 | 3.36% |
| 2000-09-30 | 17.57% |
| 1999-09-30 | 14.09% |
| 1998-09-30 | 17.21% |
| 1997-09-30 | 11.82% |
| 1996-09-30 | 16.76% |
Related Metrics
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch